Blenrep (belantamab mafodotin-blmf) vs Elrexfio (elranatamab-bcmm)
Blenrep (belantamab mafodotin-blmf) vs Elrexfio (elranatamab-bcmm)
Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate approved for the treatment of relapsed or refractory multiple myeloma in patients who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Elrexfio (elranatamab-bcmm), on the other hand, is a bispecific antibody that targets both BCMA on myeloma cells and CD3 on T cells, aiming to direct the immune system to fight the cancer, and as of my knowledge cutoff in 2023, it is an investigational agent not yet approved for use. When deciding between these two treatments, it is crucial to consult with a healthcare provider to consider factors such as the specific treatment history, the mechanism of action of the drugs, potential side effects, and the current approval status of the medications.
Difference between Blenrep and Elrexfio
Metric | Blenrep (belantamab mafodotin-blmf) | Elrexfio (elranatamab-bcmm) |
---|---|---|
Generic name | Belantamab mafodotin-blmf | Elranatamab-bcmm |
Indications | Multiple myeloma | Multiple myeloma |
Mechanism of action | Antibody-drug conjugate targeting B-cell maturation antigen (BCMA) | Bispecific antibody targeting BCMA and CD3 |
Brand names | Blenrep | Elrexfio |
Administrative route | Intravenous | Intravenous |
Side effects | Blurred vision, corneal epithelium changes, thrombocytopenia, infusion-related reactions, etc. | Currently under investigation, specific side effects not yet fully characterized |
Contraindications | Ocular toxicity, pregnancy | Not fully established |
Drug class | Antibody-drug conjugate | Bispecific antibody |
Manufacturer | GlaxoSmithKline | Pfizer |
Efficacy
Blenrep (belantamab mafodotin-blmf) Efficacy in Multiple Myeloma
Blenrep, with the active substance belantamab mafodotin-blmf, is a monoclonal antibody used to treat multiple myeloma in patients who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. It targets the B-cell maturation antigen (BCMA), which is commonly expressed on multiple myeloma cells. The efficacy of Blenrep was primarily demonstrated in a pivotal study known as DREAMM-2, a two-arm, open-label, multicenter trial. Patients treated with Blenrep showed a clinically meaningful overall response rate (ORR), with a portion of the participants achieving very good partial response (VGPR) or better, indicating a significant reduction in the disease burden.
The duration of response (DOR) for patients who responded to Blenrep treatment varied, with some experiencing sustained responses. However, it is important to note that the progression-free survival (PFS) and overall survival (OS) data were still maturing at the time of the analysis. The safety and efficacy of Blenrep continue to be evaluated in ongoing clinical trials and post-marketing studies to better understand its long-term benefits and risks in the treatment of multiple myeloma.
Elrexfio (elranatamab-bcmm) Efficacy in Multiple Myeloma
Elrexfio, also known as elranatamab-bcmm, is an investigational B-cell maturation antigen (BCMA) targeted therapy for the treatment of multiple myeloma. It is a bispecific antibody designed to bind to both BCMA on multiple myeloma cells and CD3 on T-cells, thereby facilitating the immune-mediated killing of myeloma cells. While Elrexfio is not yet approved for clinical use as of the knowledge cutoff date, early clinical trial data have shown promise in patients with relapsed or refractory multiple myeloma.
In preliminary studies, Elrexfio has demonstrated an encouraging ORR, with some patients achieving complete responses (CR). These studies have also explored the depth of response and the duration of response, which are critical factors in assessing the long-term efficacy of multiple myeloma treatments. As with any investigational therapy, the efficacy and safety profile of Elrexfio will continue to be defined through rigorous clinical trials and regulatory review processes before any potential approval for clinical use.
Regulatory Agency Approvals
Blenrep
Elrexfio
Access Blenrep or Elrexfio today
If Blenrep or Elrexfio are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us